Last updated: November 7, 2026
Methylin is a mature methylphenidate hydrochloride product marketed primarily in immediate-release tablets, chewable tablets, and oral solution forms. Its commercial position is defined by generic competition, limited brand differentiation, controlled-substance supply constraints, and the absence of meaningful remaining composition-of-matter patent protection. Methylin-specific revenue is not separately disclosed by its manufacturer, so financial analysis must rely on market structure, prescription demand, product availability, and parent-company disclosures.
What is Methylin and how is it positioned in the ADHD market?
Methylin contains methylphenidate hydrochloride, a Schedule II central nervous system stimulant approved for attention-deficit/hyperactivity disorder and narcolepsy. It competes with branded and generic versions of Ritalin, generic methylphenidate immediate-release tablets, extended-release methylphenidate products, and nonstimulant ADHD medicines.
| Attribute |
Methylin position |
| Active ingredient |
Methylphenidate hydrochloride |
| Therapeutic category |
CNS stimulant |
| Primary use |
ADHD; methylphenidate products also have narcolepsy indications |
| Controlled-substance classification |
Schedule II |
| Main dosage forms |
Immediate-release tablets, chewable tablets, oral solution |
| Typical users |
Pediatric and adolescent ADHD patients, patients requiring dose titration, patients with swallowing difficulty |
| FDA pathway |
New Drug Application and generic-equivalent competition |
| Biosimilar exposure |
None; Methylin is a small-molecule drug |
| Patent profile |
Mature, largely expired active-ingredient and basic formulation protection |
| Principal commercial risks |
Generic substitution, shortages, DEA production quotas, reimbursement pressure |
Methylin’s dosage forms create a limited niche. Oral solution and chewable tablets can be useful for children who cannot swallow tablets or require flexible titration. That utility supports continued demand, but it does not create the pricing power associated with novel extended-release delivery systems.
What is the FDA and Orange Book status of Methylin?
Methylin is an FDA-approved prescription methylphenidate product and is subject to Schedule II dispensing rules. FDA-approved methylphenidate products are generally governed by either an NDA for the branded product or an ANDA for therapeutically equivalent generic versions. The Orange Book identifies reference-listed drugs, therapeutic-equivalence ratings, patent listings, and regulatory exclusivity where applicable. [1]
The commercial implications are straightforward:
- Methylin does not benefit from current new-molecular-entity exclusivity.
- Generic methylphenidate products can compete through the ANDA pathway.
- Substitution risk is high where a therapeutically equivalent generic is available.
- Product availability, rather than patent protection, is the key near-term commercial variable.
Methylin is not a biologic. Biosimilar approval rules under the Public Health Service Act do not apply. Competition occurs through small-molecule generic approvals, not biosimilar filings.
What patents protect Methylin?
The active ingredient, methylphenidate, is an old small molecule. Basic composition-of-matter protection has expired. The immediate-release Methylin product line therefore does not have a meaningful remaining patent barrier comparable to newer extended-release methylphenidate products.
| Patent category |
Methylin exposure |
| Methylphenidate composition of matter |
Expired |
| Immediate-release tablet formulation |
No commercially significant remaining exclusivity identified |
| Oral-solution formulation |
Limited practical patent protection; generic formulation competition is possible |
| Chewable-tablet formulation |
Potential formulation or manufacturing claims may exist historically, but no material market-blocking estate is evident |
| Pediatric method of use |
Weak as a barrier because ADHD use is established and generic products can rely on approved labeling pathways |
| New chemical entity exclusivity |
Expired |
| Current Orange Book patent barrier |
No material barrier identified for conventional immediate-release Methylin presentations |
The stronger patent estates in the methylphenidate category attach to delivery technologies rather than to methylphenidate itself. Examples include osmotic-release systems, multilayer tablets, delayed-release technologies, orally disintegrating tablets, and transdermal delivery systems. Those patents may protect products such as Concerta, Jornay PM, Cotempla XR-ODT, Aptensio XR, and Daytrana, but they do not generally protect conventional Methylin immediate-release products.
When does Methylin lose exclusivity?
Methylin lost meaningful regulatory and patent exclusivity years ago. The relevant commercial loss occurred through the expiration of historic methylphenidate patents and the entry of multiple generic manufacturers, not through a recent cliff event.
| Exclusivity type |
Current status |
| New chemical entity exclusivity |
Expired |
| Orphan exclusivity |
Not applicable |
| Pediatric exclusivity |
Any historic period has expired |
| First generic exclusivity |
Expired or no longer commercially material |
| Active ingredient patent |
Expired |
| Formulation exclusivity for conventional IR products |
No material current protection |
| Market exclusivity outlook |
Continued multisource generic competition |
Methylin’s economic life is therefore a maintenance phase. The business depends on recurring prescriptions, manufacturing continuity, formulary access, and supply reliability.
How strong is the Methylin patent estate?
The Methylin patent estate is weak from an entry-barrier perspective.
Patent strength should be separated into three categories:
Immediate-release tablets
Immediate-release methylphenidate tablets have the lowest defensibility. Multiple manufacturers can produce equivalent products, and prescribers can generally switch among manufacturers without changing the active ingredient or dosing concept.
Oral solution
The oral solution has more operational value than patent value. Manufacturing controls, taste, excipient selection, container-closure systems, and controlled-substance compliance can create practical barriers, but they are not equivalent to long-lived patent exclusivity.
The product may retain demand among pediatric patients and patients needing liquid dosing. That demand supports volume but typically does not support premium pricing.
Chewable tablets
Chewable tablets can provide a differentiated dosage form. Their commercial protection remains limited unless supported by proprietary release technology, flavoring, dose uniformity, or other formulation claims. Conventional chewable methylphenidate products remain exposed to generic competition.
What market dynamics affect Methylin sales?
ADHD diagnosis and treatment demand
Methylphenidate benefits from a large and recurring ADHD treatment population. Diagnosis rates, treatment initiation, persistence, school-age prescribing, and adult ADHD treatment all influence category demand. CDC data show that ADHD is a major pediatric neurodevelopmental disorder in the United States, while commercial prescription data indicate a large stimulant market spanning methylphenidate and amphetamine products. [2]
Methylin does not capture the entire methylphenidate market. Its main demand drivers are:
- Need for immediate-release titration
- Pediatric liquid and chewable dosing
- Lower-cost stimulant treatment
- Prescriber preference for short duration of action
- Temporary substitution during shortages of other methylphenidate products
Generic substitution
Generic substitution is the central commercial pressure. Immediate-release methylphenidate is a mature multisource market, and payers generally favor the lowest-cost therapeutically equivalent product.
Methylin can retain a role where the branded dosage form is available but a generic equivalent is unavailable, where a prescriber specifies a formulation, or where a patient responds differently to inactive ingredients. Those cases do not create a broad pricing moat.
Drug shortages
Methylphenidate shortages have become a major market variable. FDA has reported shortages affecting multiple stimulant presentations, while manufacturers and wholesalers have cited demand growth, manufacturing capacity, allocation practices, and controlled-substance production limits. [3]
Shortages can temporarily improve Methylin’s unit demand when competing products are unavailable. The effect is unstable:
- Prescribers may switch into Methylin during shortages.
- Wholesaler allocations can restrict Methylin supply.
- Patients may move back to preferred extended-release products after shortages ease.
- Shortage-driven volume does not necessarily translate into durable market-share gains.
DEA quota constraints
Methylphenidate is subject to DEA aggregate production quotas. The quota system limits the amount of controlled substance that manufacturers can produce and can restrict supply even when underlying patient demand is strong. DEA has acknowledged supply-chain constraints involving prescription stimulants and has coordinated with FDA and manufacturers on availability. [4]
For Methylin, quota access and manufacturing allocation may be more important than patent status. A company with an approved product but insufficient active pharmaceutical ingredient or quota capacity may be unable to convert demand into sales.
What is the financial trajectory for Methylin?
Methylin-specific revenue is not separately reported in the public financial statements of its manufacturer. No reliable public disclosure establishes annual Methylin sales, gross margin, prescription count, or market share.
The financial trajectory is therefore best characterized as follows:
| Financial factor |
Expected effect on Methylin |
| Prescription demand |
Stable to growing with ADHD treatment prevalence |
| Net price |
Low and pressured by generic competition |
| Unit volume |
Sensitive to shortages and competitor availability |
| Gross margin |
Lower than patented extended-release stimulant products |
| Revenue visibility |
Limited because product-level sales are not disclosed |
| Working-capital exposure |
Elevated by controlled-substance inventory and allocation requirements |
| Growth profile |
Volume-led, not innovation-led |
| Strategic value |
Portfolio continuity and pediatric dosage-form coverage |
| Valuation contribution |
Likely modest relative to the parent company’s broader pharmaceutical portfolio |
If Methylin is sold within a generic or specialty-pharmaceutical portfolio, revenue can rise during periods when competing methylphenidate products are unavailable. That increase should not be treated as structural unless supported by sustained supply, payer coverage, and prescriber retention.
Parent-company financial results also cannot be used as a direct proxy for Methylin sales. Mallinckrodt, a major supplier associated with Methylin labeling, reports results across a broad portfolio that includes specialty pharmaceuticals, hospital products, and other controlled substances. The company does not separately identify Methylin revenue in a manner that permits product-level forecasting. [5]
Which companies challenge Methylin commercially?
Methylin competes with several groups rather than one direct rival.
Direct methylphenidate competitors
- Generic immediate-release methylphenidate tablet manufacturers
- Generic methylphenidate oral-solution manufacturers
- Generic chewable methylphenidate suppliers
- Ritalin and Ritalin LA products
- Other immediate-release methylphenidate labels
Extended-release competitors
- Concerta and authorized or generic versions
- Quillivant XR
- Quillichew ER
- Cotempla XR-ODT
- Aptensio XR
- Jornay PM
- Daytrana
Non-methylphenidate competitors
- Adderall and generic mixed amphetamine salts
- Vyvanse and generic lisdexamfetamine
- Dexmethylphenidate products such as Focalin
- Atomoxetine
- Guanfacine extended release
- Clonidine extended release
Extended-release products compete for treatment persistence and once-daily convenience. Methylin competes more effectively where flexible dosing, rapid onset, lower acquisition cost, or liquid administration matters.
What Paragraph IV challenges and litigation affect Methylin?
No major, currently material Paragraph IV litigation is associated with the conventional Methylin immediate-release product line. The drug’s basic patent estate is too old to create a current branded-generic litigation cycle comparable to newer extended-release products.
Paragraph IV activity is more relevant to newer methylphenidate delivery systems. Generic applicants may challenge patents covering:
- Osmotic-release tablets
- Delayed-release and evening-dosed products
- Orally disintegrating tablets
- Transdermal systems
- Extended-release bead or matrix technologies
Those cases can alter the broader methylphenidate competitive landscape, but they do not materially restore exclusivity to conventional Methylin.
What generic launch risks exist for Methylin?
Generic entry risk is already realized rather than prospective. The principal risks are commercial:
- Additional manufacturers can intensify price competition.
- Retailers and payers can shift volume away from the branded label.
- Contract manufacturers can undercut established suppliers.
- A shortage can produce temporary share gains followed by rapid normalization.
- State substitution rules can limit brand retention unless medically necessary.
- Controlled-substance inventory requirements can raise compliance and distribution costs.
The main countervailing factor is supply reliability. A manufacturer that maintains inventory during a shortage can gain prescriptions even without a patent.
How does Methylin compare with newer methylphenidate products?
| Product type |
Patent strength |
Pricing power |
Dosage flexibility |
Generic risk |
Primary advantage |
| Methylin immediate release |
Low |
Low |
High |
High |
Flexible titration and low cost |
| Methylin oral solution |
Low to moderate practical protection |
Low to moderate |
Very high |
Moderate |
Pediatric liquid dosing |
| Methylin chewable |
Low to moderate |
Low to moderate |
High |
Moderate |
Administration convenience |
| Concerta-type extended release |
Historically stronger |
Higher |
Moderate |
Patent and regulatory dependent |
Once-daily delivery |
| Jornay PM |
Higher while protected |
High |
Moderate |
Delayed by formulation patents |
Evening dosing and morning coverage |
| Quillivant XR |
Formulation-dependent |
Moderate to high |
Moderate |
Formulation-specific |
Extended-release liquid |
| Generic methylphenidate IR |
None |
Very low |
High |
Already genericized |
Lowest acquisition cost |
Methylin is commercially resilient because it occupies practical dosing niches. It is not commercially protected by a strong patent estate.
What geographic coverage and manufacturing barriers apply?
Methylin’s principal market is the United States, where FDA approval, DEA controls, controlled-substance distribution rules, and pharmacy substitution determine access. International markets may use different methylphenidate brands, dosage forms, labeling standards, and controlled-substance rules.
Manufacturing barriers include:
- Sourcing methylphenidate active ingredient
- DEA quota allocation
- Schedule II inventory controls
- Production-site compliance
- Stability and content-uniformity testing
- Child-resistant packaging
- Diversion controls
- Wholesale allocation and pharmacy distribution
These are meaningful operational barriers but do not provide the same legal protection as an unexpired patent.
What is the outlook for Methylin?
Methylin is likely to remain a durable but low-growth product. Its outlook depends on five factors:
- Continued ADHD treatment demand.
- Reliable access to methylphenidate active ingredient.
- DEA quota availability.
- Preservation of pediatric liquid and chewable demand.
- The degree to which shortages redirect prescriptions into or away from Methylin.
The most likely commercial trajectory is stable unit demand with pricing pressure and episodic shortage-related volume increases. A sustained revenue acceleration would require manufacturing expansion, improved distribution, or a differentiated formulation. Patent-driven growth is unlikely.
Key Takeaways
- Methylin is a mature methylphenidate product with no meaningful remaining active-ingredient exclusivity.
- Its commercial value comes from immediate-release, liquid, and chewable dosing options.
- Generic competition creates persistent price and substitution pressure.
- FDA shortage conditions and DEA quotas are more important than patents to near-term sales.
- Methylin-specific revenue is not publicly disclosed.
- No major current Paragraph IV litigation or patent cliff appears to change the product’s market position.
- The financial profile is volume-led, low-growth, and operationally dependent on supply reliability.
- Newer extended-release methylphenidate products have stronger formulation differentiation and greater pricing power.
FAQs
Is Methylin still under patent protection?
Conventional Methylin immediate-release products do not have a material remaining composition-of-matter patent barrier. Any historical formulation claims are not generally sufficient to prevent multisource generic competition.
Is Methylin available as a generic?
Yes. Generic methylphenidate immediate-release tablets and other methylphenidate formulations compete with Methylin. Availability varies by dosage form, manufacturer, wholesaler inventory, and shortage status.
Does Methylin have biosimilar competition?
No. Methylin is a small-molecule drug. Competition occurs through FDA ANDA generic approvals, not biosimilar applications.
Can Methylin gain market share during methylphenidate shortages?
Yes, particularly when competing extended-release or liquid methylphenidate products are unavailable. The gain may be temporary because prescriptions can move back when supply normalizes.
Is Methylin a significant revenue product for its manufacturer?
Public company filings do not separately disclose Methylin revenue. Its contribution cannot be reliably isolated from broader generic or specialty-pharmaceutical segment results.
References
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda
- Centers for Disease Control and Prevention. (2024). Data and statistics on ADHD. https://www.cdc.gov/adhd/data/index.html
- U.S. Food and Drug Administration. (2024). Drug shortages: Methylphenidate hydrochloride. https://www.accessdata.fda.gov/scripts/drugshortages/
- Drug Enforcement Administration. (2024). Aggregate production quotas for controlled substances. https://www.deadiversion.usdoj.gov/
- Mallinckrodt plc. (2024). Annual report and Form 10-K. https://www.mallinckrodt.com/investors/financial-information/
